Expression of Pro-Apoptotic Bax and Anti-Apoptotic Bcl-2 Proteins in Hydatidiform Moles and Placentas With Hydropic Changes

  • Alireza Khooei Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Fatemeh Atabaki Pasdar Department of Anatomical Sciences, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. http://orcid.org/0000-0001-6164-0069
  • Alireza Fazel Department of Anatomy and Cell Biology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mahmoud Mahmoudi Department of Immunology, Immunology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mohammad Reza Nikravesh Department of Anatomy and Cell Biology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Shahin Daneshmand Shahbazian School of Industrial Engineering, Faculty of Engineering, University of Tehran, Tehran, Iran.
Keywords: Hydatidiform mole, Abortion, Immunohistochemistry, Bcl-2, Bax

Abstract

Morphologic examination still forms the main diagnostic tool in the differential diagnosis of molar placentas. However the criteria are subjective and show considerable inter-observer variability among pathologists. The aim of the present study was to investigate the role of Bcl-2 and Bax immunostaining in the differential diagnosis of molar placentas. Bax and Bcl-2 immunohistochemical staining were performed in 19 molars (8 partial and 11 complete hydatidiform mole) and 10 non-molar (hydropic abortion) formalin-fixed, paraffin-embedded tissue samples. Ploidy analysis using flow cytometry had confirmed diploidy in hydropic abortions and complete hydatidiform moles and triploidy in partial hydatidiform moles. Bcl-2 expression was observed only in syncytiotrophoblasts, No immunoreactivity was detected in Cytotrophoblasts, and stromal cells, the total score averages of Bcl-2 immunoexpression in partial hydatidiform moles and hydropic abortions were significantly higher than in complete hydatidiform moles, whereas no significant difference was observed between partial hydatidiform moles and hydropic abortions. Bax immunoreactivity was observed in cytotrophoblasts, stromal cells and occasionally in syncytiotrophoblasts. No statistically significant difference in Bax immunoexpression total score was observed among various groups. Based on the results of this study, Bcl-2 immunostaining offers a potential adjunctive diagnostic tool to distinguish complete hydatidiform mole from partial hydatidiform mole and hydropic abortion, but not partial hydatidiform mole from hydropic abortion, Bax immunostaining cannot be helpful in this regard.

References

Refrences

Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C. Gestational Trophoblastic Diseases: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013;24(6):vi39-vi50.

Alhamdan D, Bignardi T, Condous G. Recognising gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2009;23(4):565-73.

Niemann I, Vejerslev LO, Froding L, Blaakaer J, Maroun LL, Hansen ES, et al. Gestational Trophoblastic Diseases, Clinical guidelines for diagnosis, treatment, follow-up, and counseling. Danish Med J 2015 ;62(11):A5082 1-19.

Soper JT, Mutch DG, Schink JC and American College of Obstetricians and Gynecologists. Diagnosis and treatment of gestational trophoblastic disease. ACOG Practice Bulletin No. 53. Gynecol Oncol 2004 Jun; 93(3): 575–585.

Berkowitz RS, Goldstein DP. Diagnosis and management of primary hydatidiform mole Obstet Gynecol Clin North Am 1988; 15:491–503.

Soper JT. Gestational trophoblastic disease. Obstet Gynecol 2006; 108:176-187.

Berkowitz RS, Goldstein DP. Current advances in the management of gestational trophoblastic disease. Gynecol Oncol. 2013;128(1):3–5.

Messerli ML, Parmley T, Woodruff JD, Lilienfeld AM, Bevilacqua L, Rosenshein NB. Inter- and intrapathologist variability in the diagnosis of gestational trophoblastic neoplasia. Obstet Gynecol 1987; 69: 622-662.

Howat AJ, Beck S, Fox H, Harris SC, Hill AS, Nicholson CM, et al. Can Histopathologists Reliably Diagnose Molar Malignancy? J Clin Pathol 1993; 46: 599-602.

Fukunaga M, Katabuchi H, Nagasaka T, Mikami Y, Minamiguchi S, Lage JM. Interobserver and intraobserver variability in the diagnosis of hydatidiform mole. Am J Surg Pathol 2005; 29: 942947.

Sebire NJ, Rees H. Diagnosis of gestational trophoblastic disease in early pregnancy. Current Diagnostic Pathology. 2002;8(6):430–440.

Ronnett BM, DeScipio C, Murphy KM. Hydatidiform moles: ancillary techniques to refine diagnosis. Int J Gynecol Pathol. 2011;30(2):101–16.

Hussein MR. Analysis of p53, BCL-2 and epidermal growth factor receptor protein expression in the partial and complete hydatidiform moles. Exp Mol Pathol. 2009;87(1):63–9.

Wong SYY, Ngan HYS, Chan CCW, Cheung ANY. Apoptosis in gestational trophoblastic disease correlated with clinical outcome and bcl-2 expression but not bax expression. Mod Pathol 1999; 12(3):1025–1033.

Rosai J. Female reproductive system. Ackerman’s surgical pathology. 10 ed. St Louis: Mosby; 2011. p. 1639-45.

Atabaki Pasdar F, Khooei A, Fazel A, Rastin M, Tabasi N, Peirouvi T, Mahmoudi M. DNA Flow cytometric analysis of hydatidiform moles and spontaneous abortions. IJRM 2015;13(5):269-74.

Khooei A, Atabaki Pasdar F, Fazel A, Mahmoudi M, Nikravesh MR, Khaje Delui M, Pourheidar B. Ki-67 Expression in Hydatidiform Moles and Hydropic Abortions.

Iran Red Cres Med J. 2013;15(7):590-4.

Qiao T, Nagasaka T,Harada R,Nakashima N. P53, Bax and Bcl-2 expression, and apoptosis in gestational trophoblast of complete hydatidiform mole. Placenta 1998; 19(5-6):361–369.

Fukunaga M, Ushigome S, Sugishita M. Application of flow cytometry in diagnosis of hydatidiform moles.Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc.1993;6(3):353.

Kihara M, Matsui H, Seki K, Nagai Y, Wake N, Sekiya S. Genetic origin and imprinting in hydatidiform moles. Comparison between DNA polymorphism analysis and immunoreactivity of p57KIP2. J Reprod Med.2005;50(5):307–12.

Salehnia M, Riazi FT, Taghikhani M. Placental Alkaline Phosphatase Changes in Hydatidiform mole. Cell Journal 2001;3(1):27-30.

Atabaki Pasdar F, Khooei A, Fazel A, Mahmoudi M, Tavassoli F. Detection of Sugar Chain Expression in Hydatidiform Mole Using Lectin Histochemistry. I Red Cres M J 2013;15(5):376-380.

Erol O, Suren D, Tutus B, Toptas T, Gokay A.A, Derbent A, et al. Immunohistochemical Analysis of E-Cadherin, p53 and Inhibin-α Expression in hydatidiform Mole and Hydropic Abortion. Pathol. Oncol. Res. 2015;1-7.

Banet N, DeScipio C, Murphy KM, Beierl K, Adams E, Vang R, et al. Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping. Mod Pathol. 2014 Feb;27(2):238-54.

Vang R1, Gupta M, Wu LS, Yemelyanova AV, Kurman RJ, Murphy KM, et al. Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis. Am J Surg Pathol. 2012 Mar;36(3):443-53.

Candelier JJ, Frappart L, Yadaden T, Poaty H, Picard JY, Prévot S, Coullin P. Altered p16 and Bcl-2 expression reflects pathologic development in hydatidiform moles and choriocarcinoma. Pathol Oncol Res. 2013 Apr;19(2):217-27.

Ratts VS, Tao XJ, Webster CB, Swanson PE, Smith SD, Brownbill P, Krajewsky S, Reed JC, Tilly JL, Nelson DM. Expression of Bcl-2, Bax and Bak in the trophoblast layer of the term human placenta: A unique model of apoptosis within a syncytium. Placenta 2000;21(4):361-366.

Ishihara N, Matsuo H, Murakoshi H, Laog-Fernandez J, Samoto T, Maruo T. Changes in proliferative potential, apoptosis and Bcl-2 protein expression in cytotrophoblasts and syncytiotrophoblasts in human placenta over the course of pregnancy. Endocr J 2000;47(3):317-327.

Li HW, Tsao SW, Cheung AN. Current understandings of the molecular genetics of gestational trophoblastic diseases. Placenta. 2002 Jan;23(1):20-31.

Kim CJ, Choe YL, Yoon BH, Kim CW & Chi JG (1995) Patterns of bcl-2 expression in placenta. Path Res Prac, 191, 1239-1244.

Marzioni D, Mühlhauser J, Crescimanno C, Banita M, Pierleoni C, Castellucci M. BCL-2 expression in the human placenta and its correlation with fibrin deposits. Hum Reprod. 1998 Jun;13(6):1717-22.

Toki T, Horiuchi A, Ichikawa N, Mori A, Nikaido T, Fujii S. Inverse relationship between apoptosis and Bcl-2 expression in syncytiotrophoblast and fibrin-type fibrinoid in early gestation. Mol Hum Reprod. 1999 Mar;5(3):246-51.

Wargasetia TL, Shahib N, Martaadisoebrata D, Dhianawaty D, Hernowo B. Characterization of apoptosis and autophagy through Bcl-2 and Beclin-1 immunoexpression in gestational trophoblastic disease. Iran J Reprod Med. 2015 Jul;13(7):413-20.

Halperin R1, Peller S, Sandbank J, Bukovsky I, Schneider D. Expression of the p53 gene and apoptosis in gestational trophoblastic disease. Placenta. 2000 Jan;21(1):58-62.

Al-Bozom IA. p53 and Bcl-2 oncoprotein expression in placentas with hydropic changes and partial and complete moles. Apmis 2000; 108(11):756–760.

Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 1998; 43(2): 101–11.

Published
2019-02-13
How to Cite
1.
Khooei A, Atabaki Pasdar F, Fazel A, Mahmoudi M, Nikravesh MR, Daneshmand Shahbazian S. Expression of Pro-Apoptotic Bax and Anti-Apoptotic Bcl-2 Proteins in Hydatidiform Moles and Placentas With Hydropic Changes. Acta Med Iran. 57(1):27-32.
Section
Articles